I arrived in Baltimore on October 31st to represent several biotech companies at the Korea-Maryland Bio Expo 2011. The expo was held from November 1-4 at the Baltimore Convention Center. During the expo, I talked to many different companies and individuals about Magellan/Venture Port and the companies we were representing at the expo.
The three main companies we introduced at the expo were:
1) Crystal Genomics-CrystalGenomics is a leading structural chemoproteiomics-based drug discovery and development company headquartered in Seoul, Korea with a US presence (CG Pharmaceuticals, Inc.) in Emeryville, California for multi-national clinical management.
2) Eyegene-EyeGene, Inc., a proteomics and biopharmaceutical bio-venture company, develops therapeutics, diagnostics, and technology in eye-related diseases and cancer. Its products include DRM, a product for the diagnostic of early-stage of diabetic retinopathy; Zycan, an immune stimulator, and anti-cancer and therapeutic cancer vaccine; EG-Mirotin, a therapeutics of ocular angiogenesis; and EGS, a scarless wound repair agent. EyeGene, Inc. was incorporated in 2000 and is based in Seoul, South Korea.
3) MTIG-The company developed its own technology to produce complicated structure products using titanium and the technology to mass produce them.
Our company intends to construct a strong management foundation as a professional titanium company as the advance guard in these times of competition for resources and to fulfill its tasks and roles.
